Viewing nowPregabalin 75 mg Capsule
Pregabalin 75mg
Hard capsule · Prescription medication
Hanpung Pharmaceutical Co., Ltd.

MFDS item code 201905662 · Approved 2019.08.12 · Insurance code 658107070
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it is utilized as an adjunctive treatment for partial seizures in patients with epilepsy, helping to alleviate symptoms. It is also effective in relieving symptoms in patients with fibromyalgia. This drug aids in managing pain and seizures related to various neurological disorders, thereby enhancing the quality of life for patients.
Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. This drug is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation.”) 2. Epilepsy Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, it may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this drug, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering systemic circulation, this drug is excreted primarily by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. 72 ⅹ serum creatinine concentration (serum creatinine, mg/dl) *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration schedule Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: Supplemental dose refers to a dose administered as an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended in children under 12 years of age or adolescent patients aged 12-17 years because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or behaviors, so if symptoms of depression or abnormal mood changes occur during use, patients must inform their healthcare provider immediately. Patients with hypersensitivity to any ingredient in this medication or lactose intolerance should not use it, and lactose-containing formulations should not be administered to patients with hereditary lactose metabolism disorders. Diabetic patients should be cautious, as weight gain may necessitate dosage adjustments for blood glucose control medications. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, stop taking the medication immediately. Elderly patients could experience dizziness, drowsiness, or confusion when taking this medication, and care should be taken to ensure safety until they acclimate to these effects. Vision disturbances or changes may occur, and discontinuing the medication could lead to improvement in these symptoms. Withdrawal symptoms such as insomnia, headache, nausea, and anxiety may occur when discontinuing the medication, so consultation with a healthcare provider is necessary. Patients with a history of drug abuse should be particularly cautious, as this medication may carry a high risk of abuse, and monitoring for signs of abuse is advised. Patients with impaired kidney function may require dosage adjustments, and there have been cases of improved kidney function following cessation of treatment. Patients with heart disease should exercise caution when taking this medication, especially those with severe congestive heart failure. Caution should also be observed when taken with opioid analgesics, as there is an increased risk of central nervous system depression, which can lead to serious side effects, such as respiratory suppression. Pregnant women should avoid taking this medication during early pregnancy due to the risk of congenital abnormalities in the fetus, and women of childbearing age should use effective contraception. Lactating women should either avoid breastfeeding while taking this medication or consult with their healthcare provider, as this drug can be passed into breast milk and affect the infant. Caution should be exercised while driving or operating machinery, as this medication may cause dizziness or drowsiness. Overdose of this medication may lead to symptoms such as drowsiness, confusion, and depression, necessitating immediate medical attention, and treatment such as hemodialysis may be required. Keep this medication out of reach of children and avoid transferring it to other containers. If severe rash or allergic reaction occurs, discontinue use immediately and seek medical evaluation.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that prevents exposure to air and moisture, at room temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.
A hard capsule with a reddish-brown upper part and a white lower part containing white powder
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Hanpung Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.